Anika Therapeutics
ANIK
170 hedge funds and large institutions have $616M invested in Anika Therapeutics in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 58 reducing their positions, and 19 closing their positions.
24% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.42M
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 58
0.44% less ownership
Funds ownership: 84.72% → 84.28% (-0.44%)
1% less funds holding
Funds holding: 172 → 170 (-2)
8% less capital invested
Capital invested by funds: $670M → $616M (-$54.2M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.9M |
| 2 |
Renaissance Technologies
New York
|
+$5.22M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$4.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.53M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.19M |
| 2 |
TA
Teachers Advisors
New York
|
-$8.12M |
| 3 |
AAM
AMI Asset Management
Los Angeles,
California
|
-$1.71M |
| 4 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$1.35M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.08M |
ANIK Hedge Fund Activity: Q1 2018 in Review
170 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2018, worth a combined $616M — down 8.1% from $670M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ANIK positions and 19 closed out — a net gain of 1 holder — while 58 added to existing stakes and 58 trimmed.
The largest buyer was Ameriprise, adding an estimated $12.9M. The largest seller was Wellington Management Group, cutting an estimated $9.19M.
- 170 institutional investors held Anika Therapeutics (ANIK) as of Q1 2018, down from 172 in Q4 2017.
- Funds reported $616M of Anika Therapeutics stock for Q1 2018, down 8.1% quarter-over-quarter.
- 20 funds opened new Anika Therapeutics positions in Q1 2018 and 19 closed out, a net change of +1 holder.
- The largest Anika Therapeutics buyer in Q1 2018 was Ameriprise, an estimated $12.9M added.
- The largest Anika Therapeutics seller in Q1 2018 was Wellington Management Group, an estimated $9.19M sold.
Based on aggregated 13F filings for Q1 2018.